top of page

Innovate Indiana recognizes Dr. Chandler Walker for secretome work

Indiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pathology in mice. Secretome refers to the secretions of tissue or cells that can be harvested for therapeutic or other purposes. Walker’s research, published in Neural Regeneration Research, has shown therapeutic benefits at various stages of disease progression in an ALS mouse model. In 2019 (Brain Science) Dr. Junmei Wang, Kirstin Zuzzio and Chandler Walker administered human ASC-CM (secretome) in an animal model of ALS and demonstrated that they maintained neuromuscular innervation when the treatment was given prior to the onset of this early stage pathology and when administered as a late stage treatment (at symptom onset) secretome was effective at reducing motor neuron death, delayed symptom progression, and extended the lifespan in the transgenic SOD1 mouse model. It remains unknown how well the observed response in the mouse model of ALS will translate to human therapy.

The authors were optimistic that their research sets the foundation for further investigations into the long-term benefits of early continuous ASC-CM treatment. Continued research focuses on the components of the secretome and whether exosomes play a key therapeutic role, as well as to investigate the site of action at which the dental pulp secretome therapy has its effects across different disease stages. Another area of interest was a future comparison of the therapeutic benefits of different stem cell secretomes and if the effects were repeated in mouse models of ALS.

34 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


Commenting has been turned off.
bottom of page